Unfortunately, however, acquired resistance to TKI therapies also occurs and poses a significant challenge in combating this disease.[28] Given the activity of CMTM6 in stabilizing EGFR in NSCLC cells, we next investigated the effect of CMTM6 on the treatment of NSCLC with TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.